Amylin Jumps 12% After Hiring Bankers to Advise on Sale
Shares of Amylin Pharmaceuticals (NASDAQ: AMLN) have surged roughly 12% to $25.76 on Monday after Reuters reported that the company had hired Goldman Aachs (NYSE: GS) and Credit Suisse (NYSE: CS) to act as its financial advisers in a potential sale. The company also hired Skadden Arps to provide legal advice according to Reuters. The report added that AMLN had reached out to potential buyers in the last week.
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.